Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2022
Date Filed: December 15, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the company likely has no revenue, but this specific filing does not contain financial statements or quantitative metrics.
Material Changes
The primary material event disclosed in this filing is the cessation of securities for the ticker symbol ATH, as indicated by Exhibit 99.1.
Guidance, Outlook, and Risks
This Form 6-K serves primarily to notify the SEC of the cessation of securities and to incorporate the report by reference into existing Registration Statements on Form S-8 and Form F-3. The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies beyond the cessation of the securities.
Investor Verification Checklist
- Verify the status of the "ATH" securities and the implications of their cessation.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity plans.
- Confirm the company's current cash position and runway, as this filing does not provide liquidity data.
- Check for subsequent filings regarding the company's development stage status and funding activities.